IV Iron in Association With Tranexamic Acid for Hip Fracture

• Status: Unknown status
• Trial end date: 2016-04-01
• Target enrollment: 0
• Participant gender: All

Summary

It is a prospective randomized controlled study aiming to test if tranexamic acid combined to intravenous iron before and after surgery for hip fracture in elderly can decrease peri-operative red cell transfusion.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Institut Kassab d'Orthopédie
• Treatments: Iron; Tranexamic Acid

Criteria

Inclusion Criteria:

• Patients undergoing hip fracture surgery within 72 h after trauma.

Exclusion Criteria:

• Vascular events within the last 2 months such as cerebrovascular accident (CVA), Myocardial infarction (MI), Venous Thromboembolism (VTE) and/or recurrent VTE or arterial thrombosis.

• Patients receiving anticoagulation therapy with warfarin or clopidogrel.

• History of seizures.

• Multiple fractures.

• Transfusion received during admission, prior to surgery (Hb< 8g/dl).

• Creatinine clearance less than 30 mL/min

• Known history of Factor V Leiden, protein C/S deficiency, prothrombin gene mutation, anti-thrombin deficiency, anti-phospholipid antibody syndrome, lupus anticoagulant

• Coronary stent placement within the previous 6 months

• Disseminated intravascular coagulation

• Subarachnoid hemorrhage

• Allergy for tranexamic acid

• Hypersensitivity to Iron sucrose or any component of the formulation

• Clinical signs of acute thromboembolic event

• Malignancy

• Body weight > 100kg

• Advanced Dementia